跳转至内容
Merck
CN

SML3104

Sigma-Aldrich

帕唑帕尼

≥98% (HPLC)

别名:

5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide, 5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, GW 786034, GW786034

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C21H23N7O2S
分子量:
437.52
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

检测方案

≥98% (HPLC)

形式

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear (warmed)

储存温度

2-8°C

SMILES字符串

CN1N=C2C=C(N(C3=NC(NC4=CC=C(C(S(N)(=O)=O)=C4)C)=NC=C3)C)C=CC2=C1C

InChI

1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)

InChI key

CUIHSIWYWATEQL-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

生化/生理作用

Pazopanib is an orally active receptor tyrosine kinases inhibitor against VEGFR1/2/3 (IC50 = 10/30/47 nM), PDGFR1/2 (IC50 = 84/71 nM) and c-Kit (IC50 = 74 nM), exhibiting reduced or no potency toward FGFR1/3 (IC50 = 140/130 nM), c-fms (IC50 = 146 nM), and other kinases tested (IC50 from >400 nM to >20 μM). Pazopanib exhibits anti-cancer efficacy in cultures (IC50 from 5 to 15 μg/mL; multiple myeloma migration and survival) and in mice in vivo (30-100 mg/kg/day p.o. against human MM xenografts) via angiogenesis inhibition and apoptosis induction.

象形图

Health hazardEnvironment

警示用语:

Danger

危险声明

危险分类

Aquatic Chronic 2 - Repr. 1B - STOT RE 2

靶器官

Liver

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门